Headlines about Herceptin show equality of access to costly drugs must be tackled
4th Nov 2005, 03:00 GMT
The recent press coverage on the use of Herceptin (brand name for the drug trastuzumab) for treating breast cancer in its early stages shows that issues of equal access to costly but effective drugs must be confronted, says an editorial in this week's BMJ.
Headlines about Herceptin show equality of access to costly drugs must be tackled related news:
- Government to fast-track lifesaving drugs — www.politics.co.uk | Headlines
- New review system to give faster access to cancer drugs — News
- Woman to fight Herceptin refusal — BBC News | Latest Published Stories | World Edition
- Woman waits for herceptin ruling — BBC News | UK News | England | World Edition
- 'Get past celebrity drug debate' — BBC News | In Depth | Drugs | UK Edition
- Prices for Brand-Name Rx Drugs Up 6.1% — WebMD Health Headlines
- Faster access to NHS drugs plan — BBC News | News Front Page | UK Edition
- MPs in demand for Herceptin funding — the Mail online | Health news
- Herceptin: the Cure? — KQED's Forum
- First study to confirm the benefit of anti-angiogenic therapy in patients with breast cancer — News-Medical News Feed
Latest news from EurekAlert! - Breaking News:
- Scientists capture nanoscale images with short and intense X-ray laser
- Mayo researchers offer evidence people with psoriasis greater risk for developing heart disease
- Mayo Clinic information about accelerated aging among people with rheumatoid arthritis
- ESSP launches project on the effects of global environmental change on human health
- Health inequalities are a growing problem worldwide
- HIV/AIDS linked to extensively drug resistant TB
- Higher death rate for heart attack patients with additional non-cardiac conditions
- Hormone linked to brain's cravings for food and other energy sources
- Key to acute lung injury lies in Ang2 protein
- Propane fuel cell passes muster at Exit Glacier Nature Center